Yazar "Kisakol, Gurcan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Acute-phase response after radioiodine treatment in hyperthyroidism
    (LIPPINCOTT WILLIAMS & WILKINS, 2007) Sari, Oktay; Tunc, Recep; Kisakol, Gurcan; Dostbil, Zeki; Serdengecti, Mustafa
    Purpose: Acute-phase response is an innate body defense seen during acute illnesses and involving the increased production of certain blood proteins termed acute-phase proteins. There are limited data about acute-phase response after radioiodine therapy. This study is designed to determine whether acute-phase response changes after radioiodine therapy. Materials and Methods: Twenty-six hyperthyroid patients were included in this study, aged between 25 and 69 years (mean, 47.7 +/- 10.5, 18 females and 8 males). All patients were given radioiodine therapy (8-15 mCi). Leukocyte, hemoglobin, platelet, erythrocyte sedimentation rate, and C-reactive protein (CRP) were measured before radioiodine therapy and after 24 hours, 72 hours, 1 week, 1 month, and 3 months. Free T3, free T4, TSH, thyroglobulin (Tg), antithyroid antibody, and antimicrosomal antibody (AMA) were measured before radioiodine therapy and after 1 and 3 months. Results: Mean CRP levels were 3.74, 3.90, 4.29, 5.71, 3.85, and 5.41 mg/L, respectively. There was a significant difference between the initial and the first-week results. Mean Tg levels were 68.15, 143.90, and 77.00 ng/mL, respectively, with a significant difference between the initial and the first-month and third-month results. Mean AMA levels were 158.80, 178.85, and 636.25 IU/mL, respectively, demonstrating a significant difference between the initial and the third-month and first- and third-month results. Conclusion: We have shown that radioiodine therapy causes an increase in CRP, Tg, and AMA levels. We conclude that radioiodine treatment is a cause of the increase in the CRP, Tg, and AMA levels in hyperthyroid patients.
  • Küçük Resim Yok
    Öğe
    Effects of bisphosphonates on lipid metabolism
    (MAGHIRA & MAAS PUBLICATIONS, 2008) Guney, Engin; Kisakol, Gurcan; Ozgen, A. Gokhan; Yilmaz, Candeger; Kabalak, Taylan
    OBJECTIVES: Bisphosphonates are widely used for the treatment of metabolic bone disorders and their effects on lipid metabolism have also been investigated. Some studies reported that bisphosphonates have beneficial effects on serum cholesterol levels. In this study we aimed to assess the effects of bisphosphonates on lipid levels in hyperlipidemic patients who received bisphosphonates because of osteoporosis. METHODS: 49 female patients (age: 54.2 +/- 7.2 years) with diagnosis of osteoporosis and hyperlipidemia were enrolled. Patients received alendronate 10 mg/day and they were followed up for 6 months. Pretreatment total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, apolipoprotein A1 and apolipoprotein B levels were measured and compared with post-treatment levels. RESULTS: Pretreatment and post-treatment levels of total cholesterol were 255.2 +/- 34.3; 233.02 +/- 37.0 mg/dL, triglyceride levels were 153.0 +/- 57.3; 129.1 +/- 54.4 mg/dL, and LDL levels were 170.7 +/- 30.5; 160.0 +/- 34.2 mg/dL, respectively. Reductions in total cholesterol, triglyceride and LDL-cholesterol levels were statistically significant; whereas differences in HDL-cholesterol, apolipoprotein-A1 and apolipoprotein-B levels were not significant. CONCLUSIONS: Data from our study suggest that alendronate therapy may have beneficial effects on lipid metabolism. Thus, when hyperlipidemia is detected in patients receiving bisphosphonates, it is considered reasonable to follow the patient for a while before initiating antihyperlipidemic agent to prevent unnecessary use of drugs.
  • Küçük Resim Yok
    Öğe
    Intraobserver and interobserver agreements of leg circumference measurements by tape measure based on 3 reference points
    (SAGE PUBLICATIONS INC, 2007) Tunc, Recep; Caglayan-Tunc, Aygul; Kisakol, Gurcan; Unler, Gulhan Kanat; Hidayetoglu, Taha; Yazici, Hasan
    The objective of this study was to evaluate the intraobserver and interobserver agreements in tape measurements of the ankle and calf circumference with due emphasis on the 3 main reference points, the patella, the tibial tuberosity, and the medial malleolus. The leg circumference at 2 locations was measured in 66 patients in the mornings of 2 consecutive days by 6 observers. Finally, a blinded couple measured leg circumferences at a line created on calves with a ballpoint pen of 68 outpatients to calculate interobserver agreement for lined regions. Leg circumference measurement was accepted as correct when the difference was less than 0.6 cm in 2 occasions. Intraobserver and interobserver agreements were calculated as the percentage of correct measurements. Chi-square test was used to compare intraobserver and interobserver agreements for each reference point. At the calf region, intraobserver and interobserver agreements based on the tibial tuberosity (88% and 81 %) were better than those of the patella (65% and 57%) and the medial malleolus (73% and 65%). On the other hand, at above the ankle region, the agreements (79% and 62%) were also better than those of the patella (60% and 43%) and nearly the same as those of the medial malleolus (86% and 65%). Finally, interobserver agreement of the measurements at the created line with ballpoint pen (96%) was better when compared to those of the tibial tuberosity (81%), the patella (57%), and medial malleolus (65%) (p = 0.005, p < 0.001, and p < 0.001, respectively). The results of this study suggest that the tibial tuberosity as a reference point for leg circumference measurement has better intraobserver and interobserver agreements than those of the patella and the medial malleoli.